Iovance Biotherapeutics Inc (IOVA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.07 (+0.50%), Market cap $1.54B, 52-week low–high $1.69 ~ $5.41.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cel
Financial statements, price targets, institutional (13F) holdings and related news for Iovance Biotherapeutics Inc are updated in real time on BlackAll Trade.
Iovance Biotherapeutics Inc trades at $10.07 (+0.50%). Real-time quotes and charts are available on BlackAll Trade.
Iovance Biotherapeutics Inc has a market cap of about $1.54B.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic m